Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers

Pediatric Infectious Disease Journal

Volumn 15, Issue 5, 1996, Pages 465-467

  DeVincenzo, John P ^a   Burchet, Sandra K ^b  

^a LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

acquired immunodeficiency syndrome; aphthous ulcers; human immunodeficiency virus; Thalidomide

Indexed keywords

THALIDOMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APHTHOUS ULCER; ARTICLE; CASE REPORT; CHILD; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; WEIGHT GAIN;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; ESOPHAGEAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MOUTH DISEASES; THALIDOMIDE; ULCER;

EID: 0030001687     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199605000-00019     Document Type: Article

References (14)

1. Waters MFR. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 1971;42:26-42.
2. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-uerszis-host disease [see comments]. N Engl J Med 1992;326:1055-8.
3. Holm AL, Bowers KE, McMeekin TO, Gaspari AA. Chronic cutaneous lupus erythematosus treated with thalidomide. Arch Dermatol 1993;129:1548-50.
4. Gardner MJ, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994;53:828-32.
5. Moisson YF, Janier M, Civatte J. Thalidomide for recurrent erythema multiforme [Letter]. Br J Dermatol 1992;126:92-3.
6. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations [Review]. Drug Safety 1992;7:116-34.
7. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995;20:250-4.
8. Menni S, Imondi D, Brancaleone W, Croci S. Recurrent giant aphthous ulcers in a child: protracted treatment with thalidomide. Pediatr Dermatol 1995;10:283-5.
9. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
10. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
11. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-91.
12. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87:782-5.
13. Makonkawkeyoon S, Limson PR, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-8.
14. Ochonisky S, Verroust J, Bastuji GS, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994;130:66-9.